Market Research Blog

Many consumers are making a shift to generic drugs to reduce total spending on non-prescription or OTC pain medication. Various governing bodies, such as the United States Food and Drug Administration (FDA), have implemented stringent regulations and labeling rules to ensure the safety and effectiveness of OTC pain medications. Leading players in the OTC pain medication market are collaborating with generic drug-makers to capitalize on the trend of consumer inclination towards generic versions of branded OTC pain medications, finds FMI.

The FMI study features valuable and actionable insights obtained through thorough research on OTC pain medication market. Some of the insights mentioned in the study are,

• Growing geriatric population and prevalence of chronic pain-related disorders among the elderly population is bolstering sales of OTC pain medications.
• Over 20% of the adult population of the world is already suffering from pain-related disorders and new cased of pain-related problems are reported by over 10% of the global population, which is increasing significantly every years. This is providing an impetus to growth of the OTC pain medication market.
• Increasing awareness about the side effects of pain killers, such as stomach ulcers and gastrointestinal problems, may hamper the OTC pain medication market growth.
• Developed countries will dominate the OTC pain medications market with more than half the revenue share of the market. However, developing countries in Southeast Asia will witness fastest growth in the OTC pain medication market with rapidly developing pharmaceuticals and healthcare sector in the region.

To remain ahead of your competitors, request for a sample – https://www.futuremarketinsights.com/reports/sample/rep-gb-8947

Acetaminophen Drugs Hold Majority Share in OTC Pain Medication Market

The FMI study thoroughly assesses growth of the OTC pain medication market based on various drug classes, such as Nonsteroidal anti-inflammatory drugs (NSAIDS), acetaminophen, and local anesthetics. The study finds that acetaminophens are among the most commonly purchased OTC pain medication, and this drug class holds 45% share in the revenues of OTC pain medication market. As acetaminophen is considered as a safer pain medication than other pain relievers, its demand will continue to remain high in the upcoming years, opines the FMI study.

The Consumer Healthcare Products Association (CHPA), an American trade association, recently published a study on the misuse of acetaminophen-based OTC combination products. The study found that a 28 percent decline was recorded in therapeutic misuse exposures involving acetaminophen-containing OTC combination products. The incidents of acetaminophen misuse decreased from 8,753 to 6,278 between 2007 and 2016, which is a substantial evidence for the safety and effectiveness of acetaminophen-containing OTC pain medications.

Thereby, the FMI study opines that the acetaminophen drugs will maintain a maximum share of over US$ 8.7 billion in the OTC pain medication market through 2019, and the trend will continue to persist in the coming future.

Governments take Initiatives to Spread Awareness about Safe Use of OTC Pain Medications

Despite the increasing reliance on OTC pain medications, a large consumer group is still skeptical about their effectiveness and positive impacts on health. In order to help consumers to avoid incorrect use of OTC pain medications, many governing bodies including FDA have developed guidelines and tips for patients for choosing appropriate OTC pain medications. Consumers are becoming conscious about the drug fact labeling (DFL) requirements and other regulations vis-à-vis OTC pain medications, which is influencing major dynamics of the OTC pain medication market, projects the FMI study.

The study provides a futuristic overview of the OTC pain medication market with important information about growth prospects of the market during the forecast period 2018-2028. The study predicts that the OTC pain medication market will witness healthy growth at a healthy 4.5% value CAGR to reach US$ 13 billion by the end of the assessment period.

Key Segment

Based on drug class

• non-steroidal anti-inflammatory drugs (NSAIDs)
• local anaesthetics
• acetaminophen

Based on route of administration

• oral
• tropical
• others

Based on dosage from

• tablets
• capsules
• creams
• gels
• others

Based on distribution channels

• hospital pharmacies
• drug stores
• retail stores
• e-commerce
• others

For in-depth competitive analysis, Buy Now – https://www.futuremarketinsights.com/checkout/8947

Escalating use of oral antiseptics and mouthwash, growing availability of new as well as niche products in the oral antiseptics category, and diverse price range will remain the key push factors propelling revenue growth of the oral antiseptics market. Increasing recommendations from general dental practitioners, solo and group practitioners, and dental research laboratories, strongly backed by effective marketing strategies adopted by regional and global brands is contributing heavily to steady expansion of oral antiseptics market.

Three out of 10 Europeans prefer oral antiseptics over mouthwash. While Europe has been providing the largest consumer base to oral antiseptics market players, increasing per capita consumption has been projected for the East Asian and North American consumer base. A majority of sales of oral antiseptics, i.e. over 42%, is concentrated in supermarkets/hypermarkets. However, FMI foresees a progressing demand scenario developing in the drug stores category in coming years.

Herbal oral antiseptics to rise on the back of chemical-based products

Cetylpyridinium chloride-based oral antiseptics, the bestseller over the years, will maintain a dominant value share in the market. While almost 75% of the total sales is accounted by Cetylpyridinium chloride-based oral antiseptics, a negligible share is currently contributed by the herbal segment. However, herbals are likely to emerge attractive in the long run.

In line with the concerns related to possible discomfort and side effects of strong oral antiseptics that typically include alcohol and a few other chemical components, herbal products are launched in oral antiseptics market as a milder and safer alternative to chemical-based oral antiseptics. FMI opines that alcohol-free, organic, and Ayurvedic products will particularly witness strong demand in the herbal oral antiseptics category. Relatively low competitiveness of the herbal segment operated by a lesser number of players is expected to create scope of growth for oral antiseptics market.

A visibly rising trend of strategic collaborations between major brands in oral antiseptics space is translating into an expanded consumer base of collaborating entities. The report further states that mergers and acquisitions are not only limited to industry giants but also involve a large number of regional players that are potential acquisitions candidates for MNCs. This according to the report will result in a more consolidated competition landscape in the global oral antiseptics market. Within the course of past two years, Henry Schein Inc. has accomplished eight acquisition deals traversing multiple verticals in the dental healthcare realm.

FMI forecasts a CAGR of 4.6% for the global oral antiseptics market over the 10 year projection period, 2018-2028.

Key Segment

Based on geographical region

• North America
• Europe
• Latin America
• South Asia
• East Asia
• Oceania
• Middle East & Africa (MEA)

Based on product type

• Cetylpyridinium Chloride based
• Chlorhexidine Gluconate based
• Herbal and Essential Oils

Based on distribution channel

• Retail Pharmacy
• Supermarket/Hypermarket
• E-commerce
• Drug Stores

Popular drugs preferred in seasonal affective disorder therapeutics include selective serotonin reuptake inhibitors (SSRIs), according to the report. While generics and branded drugs are widely available in seasonal affective disorder therapeutics market, Buproban and Citalopram continue to register relatively higher sales. FMI attributes this dominance to high availability of generic versions of the aforementioned drugs.

Request Sample Copy of Report: https://www.futuremarketinsights.com/reports/sample/rep-gb-8821

Bright light therapy that has been the most preferred line of treatment in seasonal affective disorder therapeutics continues to receive strong support from physicians and patients owing to positive end results. While more than half the sales of devices used in seasonal affective disorder therapeutics is accounted by light boxes, sales of desk lamps are also thriving at a brisk rate.

A highly recommended prophylactic measure involved in seasonal affective disorder therapeutics, light therapy is characterized by its rapid, reliable, and highly anti-depressant action. Extensive adoption of bright light therapy by the patients afflicted by a sub-syndromal disease and self-reporting patient population prompts at bolstered revenue visibility prospected for seasonal affective disorder treatment therapeutics in coming years.

key players

• Allergan plc.,
• Eli Lily Company,
• GlaxoSmithKline plc,
• Pfizer Inc.,
• Teva Pharmaceuticals Inc.,
• Bausch Health Companies Inc.,
• F. Hoffmann-La Roche AG, Mylan N.V.,
• Sanofi AG, Novartis AG,
• Janssen Pharmaceuticals, Inc.,
• The Sunbox Company,
• Verilux, Inc.,
• Carex Health,
• Northern Light Technologies,
• Beurer GmbH and Koninklijke Philips N.V.

Ask from the Market Research Expert @ https://www.futuremarketinsights.com/ask-question/rep-gb-8821

Demand for Combination Therapy for SAD Picking Up

The report opines that light therapy is the first line of treatment that seasonal affective disorder therapeutics providers opt for. However, a possible ineffective outcome for certain patients of SAD related psychiatric illnesses and depression creates scope of combination therapies. Some of the recently reported clinical trials emphasize potential efficacy of combination of light therapy, psychotherapy, talk therapy, and antidepressants in seasonal affective disorder therapeutics.

Inaccessibility at workplaces or during traveling has been a shortfall of light box therapy over the years. To help patients suffering from SAD explore non-conventional alternatives to seasonal affective disorder therapeutics, Austria-based med-tech startup, Active Wearables, recently launched a wearable device – Pocket Sky – providing light therapy, practically anywhere. The wearable has a wireless charging feature and the battery life is claimed to last for a couple of weeks. The Pocket Sky will potentially serve as a portable and lightweight light therapy solution to patients of seasonal affective disorder. Such innovations will continue to innovate the seasonal affective disorder therapeutics market landscape.

Inadequate availability of research data and ineffective documentation, especially related to use of bright light and blue light in light therapy, is posing a long-term challenge to rapid revenue growth of seasonal affective disorder therapeutics market. Moreover, proven adversities associated with excessive use of antidepressants also remain a concern among physicians and patients alike, limiting healthy growth prospects of seasonal affective disorder therapeutics market.

The report tracks performance of global seasonal affective therapeutics market over 2018-2028. In-depth strategic profiles of some of the leading players have been covered in the report, including Allergan plc, Eli Lily Company, GlaxoSmithKline plc, Pfizer Inc., Teva Pharmaceuticals Inc., F. Hoffmann-La Roche AG, Sanofi AG, Novartis AG, Janssen Pharmaceuticals, Inc., and Koninklijke Philips N.V. among others.

For more insights on global seasonal affective disorder therapeutics market through 2028, write in to press@futuremarketinsights.com

Download PDF Brochure @ https://www.futuremarketinsights.com/reports/brochure/rep-gb-8821

Key Segment

based on treatment type

• light boxes
• dawn stimulators
• desk lamps
• sun visors

based on disorder type

• SSRIs
• SNRIs
• NDRIs
• TCAs
• MOAIs

based on Distribution channel

• institutional sales
• retail sales

based on regions

• North America
• Latin America
• Europe
• East Asia
• South Asia
• Oceania and MEA

Rising dental lasers application in the treatment of dental diseases, including caries prevention, restorative removal and curing, cavity preparation, growth modulation, dentinal hypersensitivity, and other diagnostic purposes, has largely contributed to the growing demand rate. In addition, continued bullish prospects of global dental lasers market can be attributed to increasing adoption of these devices in soft tissue application such as wound healing, hyperplastic tissue removal, photodynamic therapy for malignancies, and photostimulation of herpetic lesions.

Global Dental Lasers Market Growth at High State of Refinement

With high efficiency, comfortable treatment, less bleeding, and more control of soft tissue, dental lasers have proven to be effective tools. Moreover, laser-based photochemical reaction are promising for bringing better results in the dentistry applications, especially for targeting cells, molecules, and pathogens. These are the critical factors anticipated to complement the future expansion of global dental lasers market.  Further, conservative soft tissue procedures using dental lasers which are covered by many insurance policies will possibly accelerate the demand growth of these devices.

To remain ahead of your competitors, request for a sample – https://www.futuremarketinsights.com/reports/sample/rep-gb-8817

Dental Surgical Lasers to Witness Maximum Demand

Based on the product type, dental surgical lasers will continue to reign supreme over dental welding lasers, accounting for around 80% of the total share of global dental lasers market, attributed by the rising prominence displayed by Nd:YAG and Er:YAG.

Diode lasers are expected to remain a hit in dentistry; soft tissue procedures using diode lasers are foreseen to generate a revenue of around US$ 196 Mn globally during the assessment period. Apart from their effectiveness in the treatment of periodontal diseases, labial frenectomy carried out using diode lasers is known to significantly reduce suturing and bleeding during intervention, resulting in lesser time of intervention, less post-operative pain, and faster wound healing.

CO2 lasers and Er:YAG Lasers have shown higher success rate in dental procedure over Nd:YAG Lasers which has been limited due to temperature build-up around the implants causing the surface to melt, despite its excellent characteristics of sterilization. With its ability to provide conservative restorative treatment, in hard tissue application, Er:YAG is placed in the fast moving growth pedestal of the global dental lasers market.

Three Key Players to Control Global Dental Lasers Market

A highly consolidated global market for dental lasers is controlled by Biolase, Inc, Dentsply Sirona, and AMD Laser, holding an approximately 87% of the total market share. With around 53% of the market share, Biolase, Inc. is deemed to be the unrivaled player of global dental lasers market, while the other two players collectively hold a market share of more than 34%. According to the report, high technological intensity and proprietary technology remain important factors for the high market consolidation. Continued focus of players on emerging Asia Pacific markets and on the development of technologically advanced products to strengthen the product portfolio and solidify their market presence will possibly open new avenues of revenue growth.

In 2017, Dentsply Sirona acquired Healthdent Technologies International, which perfectly complemented the company’s restorative and endodontics portfolio. Further, it broaden regional reach in 2018 through expansion in North America, Germany, Austria, Italy, and Shanghai.

Market Restrainers

Although the global dental lasers market is likely to maintain a positive outlook throughout the forecast period, easy availability of alternative products such as scalpels, dental drills, dental probes, and anesthetics may confine its growth. Despite the technological innovations, lack of expertise in handling the device may further impede the growth of global dental lasers market.

For in-depth insights, Download a PDF Brochure – https://www.futuremarketinsights.com/reports/brochure/rep-gb-8817

Key Segment

By Product Type

• dental surgical lasers
• dental welding laser

By End User

• dental clinics
• hospitals
• ambulatory surgical centers

By Region

• Europe
• North America
• Latin America
• Asia-Pacific Excluding China (APEC)
• China
• Middle East & Africa (MEA).

Patient pool affected by cytomegalovirus is on a consistent rise, necessitating adoption of effective treatment methods and therapies. As per a revelation by the MedlinePlus, between 50 percent and 80 percent of adults in the US have suffered from cytomegalovirus by the age of 40. Statistics as such demonstrate augmented adoption of cytomegalovirus treatment products and procedures in the future, creating sustained opportunities for the manufacturers to reap sizeable revenues.

As per the FMI report, demand for valganciclovir drug continues to be buoyant on account of effective results if taken at evenly spaced intervals, with global sales likely to surpass US$ 55.5 Mn in 2019. In addition to this, valganciclovir is less time-consuming and affordable, which is further adding to its popularity in the cytomegalovirus treatment space.

“The drug development framework for treatment of cytomegalovirus continues to be progressive, offering ample scope for development of new products and procedures. There are multiple clinical trials being performed for cytomegalovirus treatment worldwide, led by prominent regions including Europe and North America. The late-stage pipeline comprises exceptional drugs which are envisioned to enter the market. This, in turn, is likely to create favorable scenario for cytomegalovirus treatment market over the forecast period”, says FMI report.

To remain ahead of your competitors, request for a sample – https://www.futuremarketinsights.com/reports/sample/rep-gb-8665

Hospital Pharmacies Remain Highly Lucrative Channel for Manufacturers with Notable ROI Benefits

As per the report, congenital CMV infection registers substantial demand for cytomegalovirus treatment, with global sales expected to surpass over US$ 65.5 Mn in 2019. Hospital pharmacies are likely to steer sales of cytomegalovirus treatment products and procedures, owing to reliable offerings at reasonable costs. The well-informed and modern patients seek a combination of efficiency with convenience, which is making e-commerce a rapidly growing distribution channel for manufacturers to commercialize their offerings.

As per the report, high cost of cytomegalovirus treatment procedures remains a key factor hampering adoption and deterring market’s growth potential. Along with high prices, associated side effects of cytomegalovirus treatment products and procedures are denting end-user confidence. Some of the prevalent side effects associated with cytomegalovirus treatment products and procedures include neutropenia, nausea, thrombocytopenia, hematological toxicity, renal dysfunction, and so on.

Manufacturers in the cytomegalovirus treatment market are focusing on novel developments, resulting in upgraded products with ameliorated functionalities. The market players are also focusing on product availability in varying size dimensions for increased convenience of end-users. The cytomegalovirus treatment market is witnessing a series of strategic partnerships, acquisitions, and mergers, which enables the manufacturing companies to offer viable offerings by combining their production expertise. For instance, Johnson & Johnson completed the acquisition of Ci:z Holdings Co., Ltd. in 2019 for expanding its exclusive portfolio of science-based dermocosmetic beauty products.

The FMI report profiles prime opportunities in the cytomegalovirus treatment market for the forecast period of 2018 to 2028. According to the report, the cytomegalovirus treatment market is expected to proliferate at a CAGR of over 6% through 2028.

Key Segment

Based on drug type

• ganciclovir
• valganciclovir
• foscarnet
• cidofovir
• other

Get a Tailored Made Report to Match Your requirements, Ask from Market Research Expert – https://www.futuremarketinsights.com/ask-question/rep-gb-8665

Based on application

• transplantation
• organ transplantation
• congenital CMV infection
• others

Based on distribution channel

• hospital pharmacies
• retail pharmacies
• e-commerce

Based on regions

• North America
• Latin America
• Western Europe
• Eastern Europe
• Asia Pacific Including Japan
• China
• MEA.